1. Home
  2. Companies
  3. DXB
  4. Material Events

Dimerix (ASX:DXB) — Material Events

ASX:DXB · 19 articles in the last 12 months · 100% assessed

Click a band to jump to that tier

Major 2 articles Significant 15 articles Notable 2 articles Not Assessed 0 articles
Major ≥90 Significant 75–89 Notable 50–74 Routine <50 Not assessed
Significant Score 75–89
15
Dimerix Bolsters Kidney Disease Pipeline with Phase 2-Ready AKI Drug DMX-652 AcquisitionHigh
Dimerix acquires Phase 2-ready AKI drug candidate DMX-652, expanding kidney disease pipeline
17 July 2026 ·Acquisition and Clinical Trial Update ·85
Dimerix Secures Extended US Patent for DMX-652 Ahead of Phase 2 AKI TrialMedium
Dimerix secures US patent for DMX-652 with Phase 2 trial preparations underway for acute kidney injury
23 July 2026 ·Patent Grant and Clinical Trial Update ·85
Dimerix Surpasses Recruitment Target in Pivotal DMX-200 Phase 3 Trial for FSGSMedium
Dimerix completes adult recruitment in Phase 3 DMX-200 trial for FSGS, surpassing target enrollment
10 Mar 2026 ·Clinical Trial Update ·85
Dimerix Completes Recruitment in Pivotal Phase 3 Trial for Rare Kidney DiseaseMedium
Dimerix completes recruitment in Phase 3 trial of DMX-200 for FSGS, progressing toward FDA discussions
15 Dec 2025 ·Clinical Trial Update ·85
Dimerix Advances Kidney Disease Trial with Key Proteinuria DataMedium
Dimerix PARASOL data supports proteinuria endpoints for FDA approval in FSGS Phase 3 trial
8 Oct 2025 ·Clinical Data Update ·85
Dimerix’s DMX-200 Secures Orphan Drug Status in Japan, Boosting Rare Kidney Disease HopeMedium
Dimerix's DMX-200 Gains Orphan Drug Status in Japan for Rare Kidney Disease
30 Sept 2025 ·Regulatory Update ·85
Dimerix Confirms Strong Statistical Power in ACTION3 Trial with Proteinuria EndpointMedium
Dimerix confirms ACTION3 trial powered to show DMX-200 proteinuria benefit, continues Phase 3 to final endpoint
28 Apr 2026 ·Clinical Trial Update ·85
Dimerix Secures Fifth Licensing Deal and Expands Pipeline with DMX-652 AcquisitionMedium
Dimerix secures fifth licensing deal, expands pipeline with DMX-652 acquisition, and maintains strong funding through Phase 3 trial
30 July 2026 ·Quarterly Activities Report and Appendix 4C ·85
Dimerix Advances Phase 3 Trial with Strong Cash and Regulatory MomentumMedium
Dimerix advances Phase 3 trial for DMX-200 with strong cash position and regulatory progress
29 Oct 2025 ·Quarterly Activities Report and Appendix 4C ·85
FDA Endorses Proteinuria Reduction Endpoint in Dimerix’s Pivotal Kidney TrialMedium
FDA Confirms Proteinuria Reduction Endpoint for Dimerix's DMX-200 Phase 3 ACTION3 Trial
24 Dec 2025 ·Regulatory Update ·80
Dimerix Charts Growth with $1.9 Billion Licensing Pipeline and New Kidney DrugMedium
Dimerix CEO Presents Diversification Strategy and Pipeline Progress at Bioshares Summit
6 Aug 2026 ·Investor Presentation ·80
Dimerix Completes Phase 3 Recruitment, Eyes FDA Approval with $38.5M Cash BufferMedium
Dimerix completes Phase 3 trial recruitment, receives FDA input, and reports AU$38.5M cash
29 Jan 2026 ·Quarterly Activities Report and Appendix 4C ·80
Dimerix Confirms Full Adult Recruitment and Secures Funding Talks for Kidney Disease TrialMedium
Dimerix completes adult recruitment in Phase 3 trial, secures funding talks and appoints CFO
30 Apr 2026 ·Quarterly Activities Report and Appendix 4C ·80
Dimerix Takes Full Control of DMX-652 US Trial with IND Sponsorship TransferMedium
Dimerix Assumes U.S. IND Sponsorship for Phase 2 AKI Asset DMX-652
17 Aug 2026 ·Clinical Development Update ·75
Dimerix’s DMX-200 Clears Seventh Safety Review in Pivotal FSGS TrialMedium
Dimerix's ACTION3 Phase 3 Trial Passes Seventh Safety Review with No Concerns
19 Nov 2025 ·Clinical Trial Update ·75
Not Assessed Low Score, or missing data
0

No articles in this tier for the last 12 months.